Bioinsecticide Empedobacter brevis launched in China
Date:06-06-2013
A promotion meeting for empedobacter brevis insecticide created solely by Chinese Biologincal company Zhenjiang Runyu was held recently in Zhenjiang, Jiangsu Province, where industry players hold the product in high regard for its high efficiency, low toxicity and no residue features which have bright market prospects in the future.
Empedobacter brevis is created by Gao Xiaowen, a senior agronomist and the board chairman of the company; the mechanism of action is that spore will produce a kind of protein toxin during its growth, which will give off toxin leading to the death of pest after being eaten by pest. The product has a high insecticidal efficacy against lepidoptera pests such as diamondback moth, prodenia litura and cnaphalocrocis medinalis, while being very safe to human, livestock and other none-target organisms.
“empedobacter brevis insecticide was granted the national invention patent in 2004, 200-ton empedobacter brevis technical concentrate and 3000-ton empedobacter brevis suspension was permitted production by the Ministry of Industry and Information Technology in April 2012.” stated Gao Xiaowen.
In Mar, 2013, the Chinese Institute for the Control of Agrochemicals, Ministry of Agriculture (ICAMA) approved registration for the 30-bln spore/g technical concentrate and the 10-bln spore/mg suspension, after 2-year’s field trial in 4 locations, 1-year’s demonstrative trial in 2 locations, toxicity test and pathogenic test.
At present, empedobacter brevis insecticide has been put on sale in distribution networks across some 20 provinces or cities in China; the supply capacity will be able to fulfill the pest control demand of 10 million Mu/times pollution-free agro field by 2013; effort is being made to fulfill the demand of 50 million Mu/times in 3 years’ time.
The company has set up application and demonstration bases in 13 countries including Japan, South Korea, Malaysia, Vietnam, Australia, etc., as well as planning to sell the product in 25 countries including Europe and US.